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It is increasingly clear that interindividual variability in human gut microbial composition contributes to 
differential drug responses. For example, gastrointestinal (GI) toxicity is not observed in all patients 
treated with the anticancer drug irinotecan, and it has been suggested that this variability is a result of 
differences in the types and levels of gut bacterial β-glucuronidases (GUS). GUS enzymes promote drug 
toxicity by hydrolyzing the inactive drug-glucuronide conjugate back to the active drug, which damages 
the GI epithelium. Proteomics-based identification of the exact GUS enzymes responsible for drug 
reactivation from the complexity of the human microbiota has not been accomplished, however. Here, we 
discover the specific bacterial GUS enzymes that generate SN-38, the active and toxic metabolite of 
irinotecan, from human fecal samples using a unique activity-based protein profiling (ABPP) platform. 
We identify and quantify gut bacterial GUS enzymes from human feces with an ABPP-enabled 
proteomics pipeline and then integrate this information with ex vivo kinetics to pinpoint the specific GUS 
enzymes responsible for SN-38 reactivation. Furthermore, the same approach also reveals the molecular 
basis for differential gut bacterial GUS inhibition observed between human fecal samples. Taken 
together, this work provides an unprecedented technical and bioinformatics pipeline to discover the 
microbial enzymes responsible for specific reactions from the complexity of human feces. Identifying 
such microbial enzymes may lead to precision biomarkers and novel drug targets to advance the promise 
of personalized medicine.
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The gut microbiota are capable of metabolizing a myriad of drugs,1 and the biotransformation of 
these compounds by commensal intestinal bacteria can impact therapeutic outcomes by altering drug 
efficacy, and in some instances, inducing disease onset.2 Since each person harbors a unique set of gut 
microbes, drug response varies considerably between individuals.3 Although key recent reports have 
profoundly advanced our understanding of the central microbes and genes implicated in the metabolism 
of drugs2,3, only a handful of studies have focused on gut bacterial proteins implicated in the 
biotransformation of drug metabolites.4–6 Pinpointing the exact microbial enzymes that process drugs in 
the gut could lead to the development of precision biomarkers for the determination of therapeutic 
efficacy and may serve as drug targets for the modulation of the gut microbiota to optimize drug 
responses.
The gut bacterial β-glucuronidase (GUS) enzyme mediates drug-induced gastrointestinal (GI) 
toxicity by reversing glucuronidation, a Phase II transformation that inactivates and detoxifies drugs by 
conjugating them to glucuronic acid (GlcA) (Figure S1a).7 Inactive drug glucuronides created in the liver 
traverse the biliary duct to reach the intestines where they are excreted from the body.8 However, once in 
the gut, drug glucuronides have the potential to be reactivated via the hydrolytic removal of the GlcA tag 
by gut bacterial GUS enzymes. Intestinal reactivation of drug metabolites has been reported to cause 
acute, dose-limiting GI toxicities.9,10 The severity of irinotecan-induced GI toxicity varies considerably 
between patients and may be due to the interindividual variability of the human gut microbiota.11,12 
Previous analysis of the Human Microbiome Project (HMP) stool sample database revealed that the gut 
microbiota contains hundreds of putative GUS enzymes with seven unique structural classes that display 
varying catalytic efficiencies against the reporter substrates p-nitrophenyl-β-D-glucuronide (pNP-GlcA) 
and 4-methylumbelliferone-β-D-glucuronide (4-MUG).13,14 Since gut bacterial GUS enzymes process 
glucuronide conjugates with varying efficiencies, we hypothesized that interindividual differences in gut 
bacterial GUS abundance and composition might influence the differential drug response to irinotecan.
Efficient and facile strategies to identify the exact gut bacterial GUS enzymes that process drug 
glucuronides of interest from fecal material are lacking. Significant advancements in mass spectrometry 
(MS) and related bioinformatics software have made the identification and quantification of proteins from 
complex fecal supernatant possible.15–17 However, recent work has shown that shotgun-based 
metaproteomics cannot accurately identify and quantify low abundance proteins from fecal lysates.17 
Activity-based probes (ABPs) serve as powerful tools to access low abundance targets and enrich for 
functionally active proteins from fecal lysate.17,18 ABPs target the catalytic machinery of specific enzymes 
and can be outfitted with a chemical handle for target enrichment, enabling identification and quantitation 
using MS. Activity-based protein profiling (ABPP)-enabled GUS abundance data obtained from fecal 
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metaproteomes can then be correlated with ex vivo drug glucuronide processing data to identify the exact 
GUS enzymes that process drug glucuronides of interest (Figure S1b).
Using a unique pipeline that integrates ABPP-enabled GUS abundance data with ex vivo SN-38-
G processing data, we pinpoint, from human feces, the exact bacterial GUS enzymes that reactivate SN-
38, the active metabolite of the anti-cancer drug irinotecan. For the first time, we show that cyclophellitol-
based ABPs can be used to identify and quantify gut bacterial GUS enzymes from human fecal lysate. We 
identify Loop 1 (L1) GUS enzymes as key modulators of SN-38 reactivation and verify this finding with 
in vitro kinetic data and structural modeling. Finally, we use the ABPP-enabled pipeline outlined in this 
study to provide a rationale for differential GUS inhibition between human fecal samples by previously 
designed piperazine-containing GUS inhibitors.
RESULTS
Cyclophellitol-based inhibitors and ABPs target structurally diverse gut bacterial GUS enzymes. 
Cyclophellitol-based epoxide and aziridine inhibitors 1 and 2 and activity-based probes (ABPs) 3 and 4 
were previously developed to profile GUS in human cells (Figure 1a).19 Since human and bacterial GUS 
utilize the same retaining mechanism to catalyze glucuronide hydrolysis, we hypothesized that 1–4 could 
also be used to target gut bacterial GUS enzymes from the human gut.20 To confirm that 1–4 covalently 
label the catalytic glutamate in bacterial GUS enzymes, we determined the 2.4 Å resolution crystal 
structure of a bacterial GUS from the human gut commensal strain B. uniformis (BuGUS-2) in complex 
with the unsubstituted cyclophellitol-based aziridine inhibitor (2) (Table S1). Examination of the active 
site revealed inhibitor 2 covalently linked to the catalytic nucleophile (E526) of BuGUS-2 indicating that 
it is also an inhibitor of bacterial GUS (Figure 1b). Key contacts were also observed between the 
carboxylic acid of inhibitor 2 and N591 and K593, the conserved NxK motif that is essential for 
recognition of glucuronides by bacterial GUS (Figure 1b).9 In-gel labelling of wild type and mutant 
enzymes using Cy5-ABP (4) further indicated that a functionally active GUS is necessary for labelling 
and that the NxK motif is essential for recognition of ABP 4 by bacterial GUS enzymes (Figure 1c). 
The gut microbiota contains a structurally diverse assortment of bacterial GUS enzymes.13 Using 
in-gel labelling studies, we found that ABP 4 labels most exogenously purified GUS enzymes from this 
structurally and functionally diverse group of enzymes (Figure 1d). Labelling was not observed for a 
GUS from B. uniformis (BuGUS-3), which corroborates a recent study reporting that BuGUS-3 does not 
process small molecule glucuronides and poorly processes GlcA-containing polysaccharides.14 In vitro 
apparent IC50 values showed that 1–4 inhibit E. coli GUS (EcGUS), B. uniformis GUS-1 (BuGUS-1), and 
BuGUS-2 with values ranging from 20 nM to 4 µM (Figure S2). Further kinetic analysis of GUS 
inactivation by 1–4 displayed ki/KI values that mirrored the IC50 values (Table S2 and Figure S3). Taken 
Page 4 of 20






























































together, these data establish that cyclophellitol-based inhibitors and ABPs target structurally diverse and 
functionally active gut bacterial GUS enzymes.
Cyclophellitol-based ABPs label GUS enzymes in mouse fecal mixtures. As a controlled proof-of-
concept for labelling of GUS enzymes by the cyclophellitol-based ABPs, we collected fecal samples from 
wild-type germ-free mice and mice mono-associated with gus+ E. coli (EcGUSM.A.; M.A., mono-
associated). Labelling of EcGUSM.A. fecal extracts with ABP 4 revealed a single, prominent band with a 
molecular weight indicative of recombinant EcGUS (Figure S5). Heat denaturation of the fecal extracts 
from the mono-associated mice (EcGUSM.A. + H.K.; H.K., heat-killed) resulted in complete loss of labelling, 
which further establishes that these ABPs only label functionally active GUS enzymes. No significant 
labelling was observed in the fecal mixtures collected from germ-free mice which indicates that labelling 
of non-microbial protein is minimal. Finally, we show that labelling of EcGUS by ABP 4 can be blocked 
in a complex fecal setting in a dose-dependent manner using the pan-GUS inhibitor, D-glucaro-1,4-
lactone. These results demonstrate successful labelling of bacterial GUS enzymes in a controlled fecal 
matrix.
Gut bacterial GUS enzymes can be identified and quantified using cyclophellitol-based aziridine 
ABPs. After confirming that the cyclophellitol-based inhibitors and ABPs 1–4 label bacterial GUS 
enzymes in vitro and in a controlled mouse model, we performed ABPP to identify and quantify bacterial 
GUS enzymes present in human fecal samples collected from two females (F1 and F2) and two males 
(M1 and M2). We extracted total protein from human fecal lysates and enriched for GUS using the biotin-
ABP (3) (Figure 2a). Resultant samples were analyzed by liquid chromatography coupled with tandem 
mass spectrometry (LC-MS/MS) and a bioinformatics pipeline that queried the integrated gene catalog 
(IGC) using MetaLab to assemble and quantify enriched protein groups (Table S3 and Table S5).16,21 
Protein groups were defined as GUS enzymes if sequences shared similarity to either EcGUS, C. 
perfringens GUS (CpGUS), S. agalactiae GUS (SaGUS), or B. fragilis GUS (BfGUS) and contained the 
catalytic glutamates as well as the NxK motif (Figure 2a and Figure S6). Analysis of the identified GUS 
protein groups revealed significant variations in taxa, structure, and abundance of the GUS enzymes 
present in the four fecal samples (Figure 2b and Figure S7). Individuals contained between 15–29 
bacterial GUS protein groups, similar to a recent metagenomic study which showed that individuals 
harbor between 4–38 bacterial gus genes (Figure S7a).13 Phylum-level analysis revealed that all four 
individuals predominantly contained GUS enzymes from Firmicutes but displayed substantial variation in 
GUS composition at lower taxa levels (Figure 2b and Figure S7b). Further examination using a 
previously defined GUS structure rubric allowed us to analyze the identified GUS protein groups based 
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on three-dimensional structure, which revealed significant structural diversity  (Figure S7c).13 We have 
developed an ABPP-enabled proteomics pipeline to identify and quantify functionally active GUS 
enzymes present in human fecal material.
Cyclophellitol-based aziridine ABPs also target GH3 β-glucosidases. Because the human gut 
microbiota contains a diverse assortment of glycoside hydrolases (GHs), performing ABPP from fecal 
material is a veritable test of the selectivity of the GUS ABPs.22 Sequence analysis of the protein groups 
identified from human fecal extracts revealed a major off-target hit, GH3 β-glucosidases (Figure 3a and 
Table S5). The GH3 β-glucosidases enriched are structurally similar but occupy two topologically 
distinct categories that we have termed “Type I” and “Type II” (Figure S8). Manual docking analysis of 
the untagged ABP in structurally characterized GH3 β-glucosidases revealed favorable positioning of the 
catalytic nucleophile for attack of the aziridine ring (Figure 3b). Additionally, an arginine residue was 
also present (R538 and R50 in Type I and Type II, respectively) that may contact the carboxylic acid 
moiety of the probe, enabling recognition and subsequent processing of ABPs by GH3 β-glucosidases. 
We expressed and purified both a Type I and Type II β-glucosidase identified in the fecal samples and 
confirmed in vitro that they are labelled by high concentrations of ABP 3 (Figure 3c and Figure S8). 
Despite labelling of the GH3 β-glucosidase by GlcA-like aziridine probes, neither type of β-glucosidase 
processed pNP-GlcA, suggesting that off-target labelling of β-glucosidases is probably due to the reactive 
aziridine moiety of the GUS ABPs (Figure 3d, e).
Gut bacterial Loop 1 GUS enzymes are key mediators of SN-38 reactivation. After successfully 
identifying and quantifying bacterial GUS enzymes from human feces, we investigated whether we could 
identify the exact bacterial GUS enzymes responsible for SN-38 reactivation in the gut by integrating 
ABPP-enabled GUS abundance information with ex vivo SN-38-G processing data. We measured ex vivo 
SN-38-G hydrolysis by human fecal extracts, which revealed faster processing for F2 and M1 than F1 and 
M2 (Figure 4a and 4b, Figure S9). We found a strong correlation between Loop 1 (L1) GUS abundance 
and rate of SN-38-G hydrolysis when compared to total bacterial GUS abundance (Figure 4c). No 
correlation was found between either human GUS or other GUS structural classes and the rate of SN-38-
G hydrolysis (Figure S10). We validated the correlation by assessing the catalytic efficiency of SN-38-G 
processing by a panel of purified GUS enzymes from various GUS structural classes and found that 
bacterial L1 GUS enzymes process SN-38-G most efficiently (Figure 4d). We also found that F2, M1, 
and M2 were abundant in L1 GUS enzymes that had sequence identities ≥ 90% to E. eligens GUS 
(EeGUS, PDB: 6BJQ) (Table S3). We expressed and purified EeGUS and found that it processed SN-38-
G faster than all other examined GUS enzymes in vitro. A close examination of the crystal structure of 
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EeGUS reveals a hydrophobic active site pocket formed at the interface of two monomers in the L1 
tetramer (Figure 4e).23 The hydrophobic pocket formed by the oligomeric interface appears to optimally 
recognize hydrophobic small molecule glucuronides like SN-38-G. Taken together, correlation analysis 
between ex vivo processing data and ABPP-enabled GUS abundance data, further informed by in vitro 
enzyme kinetics and structural modeling, provides a molecular rationale for interindividual variation in 
SN-38 reactivation in human fecal samples, and identifies L1 GUS enzymes, particularly EeGUS, as key 
molecular regulators of efficient SN-38-G reactivation.
Piperazine containing small molecules inhibitors target gut bacterial Loop 1 GUS enzymes. Finally, 
we sought to extend these investigations to explain differential gut bacterial GUS inhibition. We have 
developed selective, potent, and non-lethal gut bacterial GUS inhibitors that block the reactivation of drug 
metabolites like SN-38-G (Figure 5a).14,24 The piperazine moiety in both UNC4917 and UNC10201652 
acts as a warhead that targets the catalytic machinery of bacterial GUS enzymes by intercepting the 
catalytic cycle.23 We find that SN-38-G processing was differentially inhibited in all four human fecal 
extracts using these GUS inhibitors (Figure 5b). Subsequent analyses reveal a strong correlation between 
inhibition and L1 GUS abundance while no correlation was observed for the other GUS structural classes, 
confirming previous work that UNC4917 and UNC10201652 act as L1-specific GUS inhibitors (Figure 
5c and Figure S11).9,24  Furthermore, we verified that UNC4510, a negative control analog of 
UNC10201652 that contains a methylated piperazine moiety, poorly inhibited SN-38-G processing for all 
GUS enzymes.23 These data show that L1-specific GUS inhibitors can block SN-38-G processing only in 
individuals whose fecal gut microbiota is highly abundant in L1 GUS enzymes.
DISCUSSION
Here we show that cyclophellitol-based epoxide and aziridine inhibitors and ABPs can target gut 
bacterial GUS enzymes. Using a combination of in vitro and in-gel assays, we find that 1–4 target 
structurally diverse GUS enzymes with varying potencies. The variation in GUS inhibition is likely due to 
differences both in oligomeric states and active site features of the bacterial GUS enzymes examined 
(Figure S4). For example, we observe more potent inhibition of E. coli GUS by the biotin-ABP (3) when 
compared to the unsubstituted aziridine inhibitor (2). Like E. eligens GUS, previous structural work has 
shown that E. coli GUS is a tetramer with a hydrophobic active site formed at the interface of its 
monomers.4,9 Thus, the increase in inhibition by ABP 3 compared to inhibitor 2 is likely due to 
hydrophobic interactions between the E. coli GUS active site and the nonpolar alkyl chain present in 3. 
Furthermore, ABP 3 and 4 displayed notable differences in inhibition for all GUS enzymes. The Cy5-
Page 7 of 20






























































ABP (4) is weaker at inhibiting GUS enzymes than the biotin-ABP (3), and this is likely due to steric 
clashes between the bulky fluorophore group and the GUS enzymes examined.
Most importantly, we show that gut microbial GUS enzymes can be identified and quantified 
from human feces using ABPP. We were interested in examining GUS sequence information obtained 
through our ABPP-enabled pipeline to better understand the structural diversity of GUS enzymes present 
in the gut microbiome and to correlate GUS structure to SN-38-G processing. By using powerful 
metaproteomic software tools like MetaLab16 and Unipept25, we also show that peptide MS data can be 
employed to obtain taxon information for GUS-producing bacterial species found in human feces. 
However, many protein groups could not be assigned to lower taxonomic ranks due to a lack of taxon-
specific distinctive peptides. Thus, in the future, strategies that both increase peptide count and yield 
longer peptides for MS analysis should be explored to improve taxonomy assignment using ABPP. 
Metagenomic sequencing could be pursued to develop a sample-specific sequence database to query 
peptides, but this approach may be economically prohibitive.26 While other methods have coupled deep-
sequencing with ABPs to uncover GUS-producing species27, we provide evidence here that ABPP alone 
can be used to obtain a strong level of taxa information for GUS-producing bacterial species from human 
fecal samples. 
An unexpected yet exciting finding from our investigation was the identification of GH3 β-
glucosidases as an off-target hits. We identified two topologically distinct GH3 β-glucosidases as off-
target hits of the GUS ABPs. Since ABPs sample enzyme function, we initially hypothesized that the 
identified GH3 β-glucosidases may process GlcA-containing substrates, but in vitro assays using pNP-
GlcA revealed that these enzymes do not process glucuronides, and are in fact, off-target hits (Figure 3d, 
e). Further assessment of previously published GH3 β-glucosidase structures reveal a solvent exposed 
active site and an arginine residue that interacts with the carboxylic acid moiety of GlcA. These features 
combined with the highly reactive nature of the aziridine moiety in the cyclophellitol-based ABP likely 
cause labelling of the GH3 β-glucosidases. The identification of only one class of off-target hits is 
remarkable given that the human gut microbiome is one of the most glycoside hydrolase rich 
environments found in nature22, and further demonstrates that cyclophellitol-based GUS ABPs are 
incredibly precise and effective probes.
Integration of ABPP-enabled GUS abundance with ex vivo SN-38-G processing data enabled the 
identification of L1 GUS enzymes as the key molecular regulators of SN-38-G turnover. Importantly, this 
predictive correlation was validated by both in vitro enzyme kinetics and structural modeling. Although 
we have strongly correlated L1 GUS enzymes to SN-38-G processing, they are lead biomarkers that will 
need to be further characterized for clinical use. For example, the ABPP methodology outlined here does 
not examine the bacterial cell uptake of these glucuronide substrates. Further studies analyzing relevant 
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gut bacterial isolates will be needed to assess cellular uptake of SN-38-G. Additionally, the gut 
microbiota contains hundreds of unique GUS enzymes, all of which are not encompassed by the four 
fecal samples used in this study. The strategy outlined here provides a foundation on which future 
proteomics and drug processing can be added to extant datasets to re-run correlation analyses and identify 
new biomarkers.
We also show that SN-38-G processing can be inhibited in complex metaproteomes using 
previously designed L1-specific GUS inhibitors and that GUS inhibition can be accurately predicted with 
probe-derived proteomics data. Interestingly, our data indicates that UNC10201652 is more potent than 
UNC4917 at inhibiting L1 GUS enzymes in fecal samples, a similar result found in a previous study.23 
Structure-activity relationships can be conducted against a large assortment of GUS enzymes found in 
fecal samples using this strategy to identify the inhibitor chemotypes that block GUS enzymes from 
reactivating drug glucuronides like SN-38-G. Coupling ABPP-enabled GUS abundance with ex vivo 
inhibition data can serve as a powerful strategy to conduct structure-activity relationships in a high-
throughput manner. Since we have a limited understanding of enzyme-substrate pairs in the microbiome, 
we believe it is imperative that high precision gut bacterial inhibitors be developed in lieu of broad-
spectrum drugs like antibiotics or inhibitors that target enzymes classes.
Recent work was published on a distinct GUS ABP composed of a GlcA warhead linked to a 
quinone methide leaving group at the anomeric position.27 The main difference between the quinone 
methide ABP and the cyclophellitol-based aziridine ABP employed here is target specificity. As noted by 
Wright and co-workers, the quinone methide ABP, once activated, has the potential to leave the enzyme 
active site and label off-target macromolecules.27 In contrast, the cyclophellitol-based aziridine ABP 
employed here reacts directly with the GUS active site in a mechanism-based fashion to form a covalent 
bond with the glutamate nucleophile, likely reducing the number of off-targets. Although labeling live 
bacteria with a quinone-methide ABP coupled with FACS sorting and 16S rRNA sequencing can give 
general taxa information on bacterial populations found in feces27, it seems less suitable for sequence-
level identification and quantification of active GUS enzymes from fecal supernatant due to the 
promiscuity of the activated quinone-methide leaving group.
In summary, we determined the composition and relative abundance of bacterial GUS enzymes 
from human fecal samples using ABPP. We utilized these data to identify the key modulators of SN-38 
reactivation and to rationalize differential GUS inhibition across fecal samples. While we focused on SN-
38-G metabolism in the present study, the combination of proteomics data and functional assays can be 
employed to pinpoint specific GUS enzymes implicated in the reactivation of other drug glucuronides. 
Furthermore, proteomics-activity correlations provide a universal tool to identify a specific molecular 
target for any enzyme activity in the microbiome, an approach that is only limited and facilitated by the 
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current set and continued development of ABPs that target gut bacterial enzymes.17–19,27–30 Together, the 
data gained from this ABPP approach enables the identification of potential gut bacterial drug targets for 
the molecular modulation of the gut microbiota and can be employed to reveal highly precise biomarkers 
for possible diagnostic development in the era of personalized medicine.
METHODS
Full details for all materials and methods are provided in the Supporting Information.
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Figure 1. Cyclophellitol-based inhibitors and ABPs label structurally diverse gut bacterial GUS enzymes. 
(a) Cyclophellitol-based epoxide and aziridine inhibitors 1 and 2 and ABPs 3 and 4. (b) A 2.4 Å 
resolution crystal structure (PDB: 6NZG) of inhibitor 2 bound to BuGUS-2. Inset shows 2Fo – Fc map 
(after refinement) at 1 σ and distances are shown in Å. (c) In-gel fluorescence labelling of wild type and 
inactive GUS controls by ABP 4. E. coli GUS (EcGUS), heat-denatured E. coli GUS (EcGUSH.D.), B. 
uniformis GUS-1 (BuGUS-1), B. uniformis GUS-2 (BuGUS-2), and BuGUS-1 and BuGUS-2 mutants 
(BuGUS-1NxK and BuGUS-2NxK) where the asparagine and lysine residues of the NxK motif have been 
mutated to alanines. (d) In-gel fluorescence labelling of structurally diverse gut bacterial GUS by ABP 4. 
B. fragilis GUS (BfGUS), B. uniformis GUS-3 (BuGUS-3), B. ovatus GUS (BoGUS), and B. dorei GUS 
(BdGUS). All wild type and mutant proteins were exogenously purified.
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Figure 2. Probe-enabled proteomics and structure-guided bioinformatics enable identification and relative 
quantitation of bacterial GUS enzymes from human fecal samples. (a) General schematic of the probe-
enabled proteomics pipeline used to identify and quantify GUS from fecal material. In brief, (i) proteins 
are extracted from feces using ultrasonication, (ii) GUS enzymes are enriched using the pre-clicked 
biotin-ABP (3) and streptavidin beads, and (iii) MetaLab is used to query the integrated gene catalog 
using raw MS data to assemble and quantify protein groups.  Only proteins with the GUS fold and active 
site features, including the catalytic glutamates (E) and NxK motif, are defined as GUS enzymes. (b) 
Heatmap of identified GUS protein groups organized by sequence similarity and color coded by 
abundance. GUS abundance is represented by LFQ intensities, which are normalized and combined 
peptide signal intensities as determined by the MaxLFQ algorithm in MaxQuant. Further taxonomic 
classifications are shown below the abundance heatmap. Unknown refers to protein groups where the 
phylum assignment was ambiguous due to mapping of GUS peptides to multiple phyla. Sequence-level 
information for each protein group can be found in Table S3. 
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Figure 3. β-glucosidase is a specific off-target of GUS ABPs. (a) Protein abundance of GUS, Type I β-
glucosidase, and Type II β-glucosidase identified from human fecal samples. (b) Conserved active sites of 
topologically distinct Type I (PDB: 5K6M) and Type II (PDB: 5WAB) β-glucosidases with the untagged 
ABP manually docked in PyMol. Distances are shown in Å. (c) Type I and Type II β-glucosidase 
inhibition by the biotin-ABP (3). (d) Chemical structures of 2-nitrophenyl β-D-glucopyranoside (2-NP-
Glc) and p-nitrophenyl-β-D-glucuronide (pNP-GlcA). (e) In-vitro processing of 2-NP-Glc and pNP-GlcA 
by Type I and Type II β-glucosidases. All percent activity and rate values shown are mean values ± 
standard deviation using N=3 biological replicates.
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Figure 4. ABPP coupled with ex vivo processing data provides a molecular rationale for GUS-mediated 
SN-38 reactivation. (a) SN-38 glucuronide (SN-38-G) is the inactive metabolite of the topoisomerase I 
inhibitor irinotecan and is reactivated to SN-38 in the gut by bacterial GUS enzymes, resulting in acute, 
dose-limiting GI toxicity. (b) Ex vivo processing of SN-38-G by human fecal protein extracts. (c) 
Correlation analysis between total bacterial GUS abundance and Loop 1 (L1) GUS abundance against 
SN-38-G processing. (d) In vitro catalytic efficiencies of SN-38-G processing for a representative panel 
of GUS enzymes of different loop types. mini-Loop 1 (mL1); Loop 2 (L2); mini-Loop 2 (mL2); mini-
Loop 1, mini-Loop 2 (mL1, mL2); No Loop (NL); N-Terminal Loop (NTL) (e) Quaternary structure of E. 
eligens GUS (EeGUS, PDB: 6BJQ) with SN-38-G manually docked in PyMol.
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Figure 5. ABPP coupled with ex vivo processing data explains differential propensities for GUS 
inhibition. (a) Structures of L1 GUS inhibitors, UNC4917, UNC10201652, and the poor inhibitor, 
UNC4510 (negative control). (b) Inhibition of SN-38 reactivation in human fecal samples by selective 
bacterial GUS inhibitors. All percent activity values shown are mean values ± standard deviation using 
N=3 biological replicates. (c) Correlation analysis between L1 GUS abundance and inhibition data for 
each GUS inhibitor.
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